http://gut.bmj.com Gut RSS feed -- recent Leading article articles Gut 0017-5749 http://hwmaint.gut.bmj.com/homepage/GUT_95x60.gif http://gut.bmj.com http://gut.bmj.com/cgi/content/short/74/1/9?rss=1 Despite significant advances in biologic and small molecule treatments and the emergence of combination therapies to treat inflammatory bowel diseases (IBD) a large unmet need remains to control intestinal inflammation. New approaches targeting several pathways simultaneously with a favorable safety profile and agents that trigger anti-inflammatory pathways to drive durable resolution of inflammation are needed. This article discusses novel cellular immunotherapies and immune cell depleting therapies in IBD, including CAR-T cell approaches, Tr1 and T regulatory (Treg) cells and cell depleting antibodies such as rosnilimab. These novel approaches have the potential to overcome current therapeutic limitations in the treatment of IBD.

]]> 2024-12-10T06:50:44-08:00 info:doi/10.1136/gutjnl-2024-332919 hwp:master-id:gutjnl;gutjnl-2024-332919 BMJ Publishing Group 2025-01-01 Leading article 74 1 9 14